Cite

    Mitchell, E. et al. (2018). Rheumatic immune-related adverse events secondary to anti–programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. European journal of cancer. pp. 88-102. [Online].